The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study

Table 1 The demographic data of the enrolled participants

	Participants without priming (n = 71)	Participants primed with A/Indonesia/05/2005 (n = 34)	Participants primed with A/Vietnam/1194/2004 and A/Indonesia/05/2005 (n = 26)
Age group (years) (%)
20-29	33 (46)^a	21 (62)	10 (38)
30-44	27 (38)	10 (29)	13 (50)
45-60	11 (15)	3 (9)	3 (12)
Gender, Female (%)	51 (72)	8 (24)	2 (8)

^aBecause the percentage in each age group was rounded off, the sum of the numbers in the column was added up to 99% only.

ISSN: 1471-2334